Hi Crisendy & All, Yes a bit frustrating, but how many times have we seen SP dips happen here for no reason, only for it to shoot back up again on no news?
@Eqz was happy to grab some lol. Good on you mate & I agree with @christophe, maybe some pre Xmas selling & stop losses hit. I don’t care, and here is why:
So while we are waiting on the Janssen/PIQ collaboration data, here is a little snippet from Janssen website on collaboration titled “The World is our Lab”
For new people here, Janssen are collaborating with the National Kidney Foundation (USA) also to improve screening & awareness of CKD on the launch of Invokana extra indications in CKD/CVD, so Not For Profits also.
Janssen have also collaborated with Vifor, a Swiss Pharma that are cardio/renal specialists & well established in the USA to market Invokana. I think this is all due to kick of in Jan 2020. It takes a while from FDA approval for new drug labelling to be available & in the meantime, there has been a lot of policy being written, not just by Govt, but also we should be seeing new Standards of Care coming out in Jan 2020 for Diabetes (from previous interviews/articles posted here).
If you read the US Govt HHS Policy on Kidney Health, posted on Thursday, it’s evident that there is collaboration between Govt, the medical profession, NKF and other stakeholders, including commercial to tackle the CKD problem. It is worth skim reading if you want a good understanding of how things will pan out in the DKD/CKD space in the USA, with diabetes being a major cause of ESRD. There are a lot of stats & graphs at the end of the article, but the crux of the problem for the US Govt is this:
With validation of PromarkerD with large clinical trials, and an NPV (Negative predictive value) of 98%, so this effectively rules out CKD/DKD in the next 4 years in 98% of patients, and a PPV (positive predictive value) of 86% to predict CKD/DKD in diabetics within the next 4 years; the benefits of that are huge in planning care & screening timelines for patients and also detecting early CKD before it is too late & showing up in currently available blood & urine testing, now that there is at least one drug available for this indication. (See ASX announcements for validation of these comments/numbers).
This data is what awarded us CE mark in the EU, and that is a very big deal. We are awaiting US news & with all going on I’m so happy PIQ canned that US deal with Prism Health Dx, even though it caused SH some pain at the time.
Quiagen (USA) was another collaborator for a urinary tract cancer test for companion diagnostic with Janssen. This test is now available through Labcorp, one of the biggest Tier 1 labs in the USA. Sound familiar from Richard’s comments in previous ANNs?
GLTAH. It’s just a wait on biotechs, regulatory approvals etc, it’s not that the company aren’t “doing things”. Some don’t have the patience & that won’t be our problem in the long run. Speed humps.
PIQ Price at posting:
26.5¢ Sentiment: Buy Disclosure: Held
(20min delay)